We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In ...

Travere Therapeutics is positioned for upside as FILSPARI sales accelerate and the critical FSGS PDUFA decision approaches in April. Read more on TVTX stock here.

Travere Therapeutics Inc. (NASDAQ: TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, ...

The National Organization for Rare Disorders (NORD®) is calling attention to rare diseases as a significant and growing public health challenge affecting more than 30 million Americans. Fewer than 5 ...

Travere Therapeutics (TVTX) is back in focus after Q4 2025 results topped earnings expectations, supported by record demand for FILSPARI, with investors also weighing recent FDA approvals and late ...

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on the U.S. Food and Drug Administration’s review timeline for a potential focal ...

Q4 2025 Management View CEO Eric Dube stated that "2025 was an incredible year for Travere, one that was defined by achieving ...

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Travere (TVTX) delivered earnings and revenue surprises of +16.73% and -8.97%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of ...

Inc.), , a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address ...